FORA Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

FORA Capital’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,439	Closed	-$939K	–	446
2024 Q2	$939K	Sell	3,439 -2,570	-43%	-$747K	0.11%	222
2024 Q1	$2.08M	Sell	6,009 -236	-4%	-$77.6K	0.17%	155
2023 Q4	$2.02M	Buy	6,245 +3,562	+133%	+$1.12M	0.17%	160
2023 Q3	$962K	Sell	2,683 -1,352	-34%	-$522K	0.08%	251
2023 Q2	$1.53M	Buy	4,035 +3,226	+399%	+$1.31M	0.22%	124
2023 Q1	$388K	Sell	809 -760	-48%	-$356K	0.04%	397
2022 Q4	$660K	Buy	1,569 +400	+34%	+$161K	0.11%	227
2022 Q3	$488K	Buy	+1,169	New	+$583K	0.09%	256
2022 Q2	–	Sell	-1,931	Closed	-$1.12M	–	435
2022 Q1	$1.12M	Buy	+1,931	New	+$1.16M	0.2%	144
2021 Q2	–	Sell	-340	Closed	-$194K	–	886
2021 Q1	$194K	Buy	+340	New	+$201K	0.06%	294

Other funds holding BIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

FORA Capital's BIO Position: Q3 2024 in Review

FORA Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2024, closing a stake of 3,439 shares — an estimated $939K sold.

FORA Capital first reported a position in BIO in Q1 2021 and held it in 10 quarters. The position peaked at $2.08M in Q1 2024. 438 funds tracked by Wall St. Rank hold BIO as of Q3 2024.

FORA Capital reported no remaining Bio-Rad Laboratories Class A position as of Q3 2024 after selling out during the quarter.
FORA Capital sold 3,439 Bio-Rad Laboratories Class A shares in Q3 2024, an estimated $939K.
FORA Capital first reported a position in Bio-Rad Laboratories Class A in Q1 2021 and held it in 10 quarters.
FORA Capital's Bio-Rad Laboratories Class A position peaked at $2.08M in Q1 2024.
438 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2024.

Based on FORA Capital's 13F filing for Q3 2024, filed 13 Nov 2024.